Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $874.58 million. The enterprise value is $568.91 million.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 69.58 million shares outstanding. The number of shares has increased by 10.19% in one year.
| Current Share Class | 69.58M |
| Shares Outstanding | 69.58M |
| Shares Change (YoY) | +10.19% |
| Shares Change (QoQ) | -1.89% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 58.19% |
| Float | 38.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.49 |
| Forward PS | 9.33 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.40 |
| Quick Ratio | 3.19 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.54% and return on invested capital (ROIC) is -17.92%.
| Return on Equity (ROE) | -30.54% |
| Return on Assets (ROA) | -14.57% |
| Return on Invested Capital (ROIC) | -17.92% |
| Return on Capital Employed (ROCE) | -32.47% |
| Revenue Per Employee | $266,797 |
| Profits Per Employee | -$429,003 |
| Employee Count | 286 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $6.08 million in taxes.
| Income Tax | 6.08M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.02% in the last 52 weeks. The beta is 1.17, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +47.02% |
| 50-Day Moving Average | 12.39 |
| 200-Day Moving Average | 12.80 |
| Relative Strength Index (RSI) | 58.69 |
| Average Volume (20 Days) | 825,818 |
Short Selling Information
The latest short interest is 6.50 million, so 9.34% of the outstanding shares have been sold short.
| Short Interest | 6.50M |
| Short Previous Month | 5.41M |
| Short % of Shares Out | 9.34% |
| Short % of Float | 16.86% |
| Short Ratio (days to cover) | 7.82 |
Income Statement
In the last 12 months, Zymeworks had revenue of $76.30 million and -$122.70 million in losses. Loss per share was -$1.62.
| Revenue | 76.30M |
| Gross Profit | -60.20M |
| Operating Income | -121.70M |
| Pretax Income | -115.98M |
| Net Income | -122.70M |
| EBITDA | -113.02M |
| EBIT | -121.70M |
| Loss Per Share | -$1.62 |
Full Income StatementBalance Sheet
The company has $225.78 million in cash and $18.53 million in debt, giving a net cash position of $305.67 million or $4.39 per share.
| Cash & Cash Equivalents | 225.78M |
| Total Debt | 18.53M |
| Net Cash | 305.67M |
| Net Cash Per Share | $4.39 |
| Equity (Book Value) | 338.77M |
| Book Value Per Share | 4.91 |
| Working Capital | 212.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$110.04 million and capital expenditures -$1.99 million, giving a free cash flow of -$112.04 million.
| Operating Cash Flow | -110.04M |
| Capital Expenditures | -1.99M |
| Free Cash Flow | -112.04M |
| FCF Per Share | -$1.61 |
Full Cash Flow StatementMargins
Gross margin is -78.89%, with operating and profit margins of -159.49% and -160.80%.
| Gross Margin | -78.89% |
| Operating Margin | -159.49% |
| Pretax Margin | -152.82% |
| Profit Margin | -160.80% |
| EBITDA Margin | -148.11% |
| EBIT Margin | -159.49% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.19% |
| Shareholder Yield | n/a |
| Earnings Yield | -14.03% |
| FCF Yield | -12.81% |
Analyst Forecast
The average price target for Zymeworks is $19.50, which is 55.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.50 |
| Price Target Difference | 55.13% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 14.82% |
| EPS Growth Forecast (5Y) | -7.10% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.15 |
| Piotroski F-Score | 3 |